Tag: Ankylosing spondylitis
-
RINVOQ Survey
The Common Drug Review (CDR) and Institut national d’excellence en santé et en services sociaux (INESSS) are currently welcoming patients to provide input to patient organizations on the manufacturer’s submission for upadacitinib (Rinvoq) for the treatment of ankylosing spondylitis (AS).Organizations supporting patients living with ankylosing spondylitis (AS) develop these patient input submissions whenever a drug…